LY6K and breast carcinoma: LY6E, together with LY6K, has also been implicated in breast cancer proliferation by altering TGFβ-dependent breast cancer cell physiology, resulting in increased immune checkpoint molecules PD-L1 and CTLA4 in tumor-infiltrating T regulatory cells yet decreased natural killer (NK) cell activation [43].